Business
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 -
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\nNet revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter\n\n\nIncreases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS® (voclosporin)\n\n\nConference call to be hosted today at 8:30 a.m. ET\n\n\n EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts are expressed in U.S. dollars.\n\n\nTotal net revenue was $41.5 million for the three months ended June 30, 2023, compared to $28.2 million in the prior year three months ended June 30, 2022, representing growth of approximately 47% year over year. Year to date net revenue increased to $75.9 million for the six months ended June 30, 2023 compared to $49.8 million for the same time period for 2022, representing growth of approximately 52% period over period.\n\n\n“We are extremely pleased with our results in the second quarter of 2023. Building on three successful quarters in a row, this represents our most successful quarter to date from a net revenue perspective,” said Peter Greenleaf, President, and Chief Executive Officer of Aurinia. “Strong commercial execution continues as we see further utilization of LUPKYNIS® (voclosporin) across the lupus nephritis marketplace. Moreover, we are excited by the depth of usage in nephrology and the continued expansion into rheumatology. Our marketing and selling efforts continue to produce patient start forms (PSFs), patients on therapy (POT), wallets shipped, and net product revenue at or near all-time highs.”\n\n\nFor the fiscal year 2023, the Company is increasing its net product revenue guidance to a range of $150 - $160 million for net product sales of LUPKYNIS. The guidance range is based on assumptions regarding PSF run rates, consistent conversion rates, time to convert, persistency, and pricing.\n\n\nSecond Quarter 2023 and Recent Highlights\n\n\n\nArthritis & Rheumatology published full results of AURORA 2, a Phase 3, double-blind, placebo-controlled extension study out to 3 years, demonstrating that kidney preservation, sustained renal response, and reductions in steroid use were achieved with LUPKYNIS with mycophenolate mofetil (MMF) and low-dose steroids, compared to MMF and low-dose steroids alone.\...